Health Affairs January 22, 2025
Chuanzi Yue, Marisa Miraldo

With drug prices rising faster than inflation and outpacing many other health care costs, policy makers are under increasing pressure to find sustainable solutions that balance patient access, innovation, and affordability. We believe centralized procurement—in which governments negotiate drug prices directly with pharmaceutical companies—can be an important tool to address these challenges. This includes the recent introduction of Medicare price negotiations through the Inflation Reduction Act (IRA) of 2022.

For the first time, Medicare is empowered to negotiate prices for high-cost drugs, a move that has triggered concerns among pharmaceutical companies and some stakeholders. These industry voices warn that such measures could significantly reduce profit margins, hinder innovation, and negatively impact patient outcomes. Some academic sources echo these concerns, suggesting...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Congress / White House, Govt Agencies, HHS, Insurance, Medicare, Pharma, Pharma / Biotech
Musk's team accesses Medicare, Medicaid records
Musk’s DOGE Reportedly Digging Into Medicare Payment System
DOGE turns focus to CMS spending, contracts, news report says
Are Medicare Fee Schedules Appropriate For Commercial Populations?
Medicare's 2025 physician pay cut, explained

Share This Article